Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Clin Cancer Res. 2019 Jun 12;25(18):5503–5512. doi: 10.1158/1078-0432.CCR-19-0104

Figure 4: Candidate predictive markers in immunotherapy treated melanoma cohort C by NanoString DSP.

Figure 4:

Kaplan Meier 5-year survival and progression free survival curves of immunotherapy treated melanoma patients in Yale cohort C. (A) OS by CD8 counts in CD68+ compartment, p=0.0119 (B) PFS by CD8 counts in CD68 compartment, p=0.0082 (C) Response to ICIs by CD8 counts in CD68+ compartment, p=0.014 (D) OS by PD-L1 in CD68+ compartment, p=0.0032 (E) PFS by PD-L1 in CD68+ compartment, p=0.0072 (F) Response to ICIs by PD-L1 in CD68+ compartment, p=0.011 (G) OS by PD-L1 in tumor compartment, p=0.072 (E) PFS by PD-L1 in tumor compartment, p=0.054 (F) Response to ICIs by PD-L1 in tumor compartment. Survival analysis by log-rank (Mantel-Cox) test. Two-tailed Mann-Whitney U test, bars represent means with standard deviation. *Denotes statistical significance p<0.05.